A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)
This is a Phase 3, randomized, multi-center, double-blinded, active-controlled study that is
 primarily designed to assess the Annualized Relapse Rate (ARR) and safety/tolerability of
 ublituximab/oral placebo (TG-1101; UTX) as compared to teriflunomide/IV placebo in subjects
 with Relapsing MS.
Inclusion Criteria:

 -  18-55 age

 -  Diagnosis of RMS (McDonald criteria 2010)

 -  Active disease

 -  Expanded disability status scale (EDSS) 0-5.5 (inclusive) at screening

 Exclusion Criteria:

 -  Treatment with prior Anti-CD20 or other B cell directed treatment

 -  Treatment with the following therapies at any time prior to randomization:
 Alemtuzumab, Natalizumab, Teriflunomide, Leflunomide and Stem cell transplantation

 -  Diagnosed with Primary Progressive MS (PPMS)

 -  Pregnant or nursing